Arachidonic Acid
Arachidonic Acid, a lipid. Primary ω-6 precursor for the 2-series prostaglandins/thromboxanes (COX pathway), 4-series leukotrienes (5-LOX), and… Oral half-life 3 d.
Primary ω-6 precursor for the 2-series prostaglandins/thromboxanes (COX pathway), 4-series leukotrienes (5-LOX), and multiple HETEs (12-/15-LOX, CYP450) — the canonical pro-inflammatory eicosanoid substrate. Incorporated into membrane phospholipids (sn-2 position) and released by phospholipase A2 on stimulus. Supplementation at modest doses raises plasma and RBC ARA but produces limited downstream eicosanoid signal because release is demand-driven; high-dose bodybuilding use (~1.5 g/day) aims to amplify training-induced prostaglandin signalling.
F 0.9 REMOVED as an R6 stored default. PMID:22188761 is a 4-week supplementation trial measuring plasma phospholipid ARA, prostanoids and clinical chemistry; it states no PK parameter at all. A dietary fatty acid has no IV arm, so no absolute bioavailability is obtainable. Removal is numerically a no-op — 0.9 is the consumer default — and the record now stops claiming the figure was measured.
Pharmacokinetics
- Oral — t½ 3.0 d
Related compounds
- EPA/DHA — caution
Sources: PMID:22188761